Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Pathological gambling is associated with altered opioid system in the brain: Reduced feeling of euphoria when compared to healthy volunteers

  • Why depression and aging are linked to increased disease risk

  • Birth season affects your mood in later life, new research suggests

  • Highly Connected CEOs More Likely to Broker Mergers and Acquisitions That Harm Firms

  • Irritable bowel syndrome: Males report more social stress than females

  • New test to help brain injury victims recover

  • Panic attacks associated with fear of bright daylight

  • Fish intake associated with boost to antidepressant response

  • Aspirin shown to benefit schizophrenia treatment

  • American Alzheimer's plan milestones must be strengthened to meet goal by 2025, experts say

  •